Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):609-14. doi: 10.1016/j.ijrobp.2012.05.050. Epub 2012 Aug 3.
Use of postmastectomy radiation therapy (PMRT) in breast cancer patients with 1-3 positive nodes is controversial. The objective of this study was to determine whether the size of nodal metastases in this subset could predict who would benefit from PMRT.
We analyzed 250 breast cancer patients with 1-3 positive nodes after mastectomy treated with contemporary surgery and systemic therapy at our institution. Of these patients, 204 did not receive PMRT and 46 did receive PMRT. Local and regional recurrence risks were stratified by the size of the largest nodal metastasis measured as less than or equal to 5 mm or greater than 5 mm.
The median follow-up was 65.6 months. In the whole group, regional recurrences occurred in 2% of patients in whom the largest nodal metastasis measured 5 mm or less vs 6% for those with metastases measuring greater than 5 mm. For non-irradiated patients only, regional recurrence rates were 2% and 9%, respectively. Those with a maximal nodal size greater than 5 mm had a significantly higher cumulative incidence of regional recurrence (P=.013). The 5-year cumulative incidence of a regional recurrence in the non-irradiated group was 2.7% (95% confidence interval [CI], 0.7%-7.2%) for maximal metastasis size of 5 mm or less, 6.9% (95% CI, 1.7%-17.3%) for metastasis size greater than 5 mm, and 16% (95% CI, 3.4%-36.8%) for metastasis size greater than 10 mm. The impact of the maximal nodal size on regional recurrences became insignificant in the multivariable model.
In patients with 1-3 positive lymph nodes undergoing mastectomy without radiation, nodal metastasis greater than 5 mm was associated with regional recurrence after mastectomy, but its effect was modified by other factors (such as tumor stage). The size of the largest nodal metastasis may be useful to identify high-risk patients who may benefit from radiation therapy after mastectomy.
在 1-3 个阳性淋巴结的乳腺癌患者中使用术后放疗(PMRT)存在争议。本研究的目的是确定该亚组中淋巴结转移的大小是否可以预测谁将从 PMRT 中受益。
我们分析了在我们机构接受现代手术和系统治疗的 250 例 1-3 个阳性淋巴结的乳腺癌患者。其中 204 例患者未接受 PMRT,46 例患者接受了 PMRT。通过测量最大淋巴结转移的大小(小于或等于 5 毫米或大于 5 毫米),将局部和区域复发风险分层。
中位随访时间为 65.6 个月。在整个组中,最大淋巴结转移测量值为 5 毫米或更小的患者中,区域复发率为 2%,而转移测量值大于 5 毫米的患者为 6%。仅对于未接受放疗的患者,区域复发率分别为 2%和 9%。最大淋巴结尺寸大于 5 毫米的患者区域复发的累积发生率明显更高(P=.013)。未接受放疗的患者中,最大淋巴结转移尺寸为 5 毫米或更小的患者,5 年区域复发累积发生率为 2.7%(95%置信区间 [CI],0.7%-7.2%),转移尺寸大于 5 毫米的患者为 6.9%(95% CI,1.7%-17.3%),转移尺寸大于 10 毫米的患者为 16%(95% CI,3.4%-36.8%)。最大淋巴结尺寸对区域复发的影响在多变量模型中变得不显著。
在未接受放疗的行乳房切除术的 1-3 个阳性淋巴结的患者中,淋巴结转移大于 5 毫米与乳房切除术后区域复发相关,但受其他因素(如肿瘤分期)的影响。最大淋巴结转移的大小可用于识别可能从乳房切除术后放疗中受益的高危患者。